Alkem Laboratories Ltd launched Pertuza injection (420mg/14mL), a biosimilar version of Roche’s pertuzumab, for the treatment of HER2-positive breast cancer. Developed indigenously by Alkem’s biotech subsidiary, the biosimilar demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product in pivotal phase 3 clinical trials, the company confirmed.
Making Cancer Therapy More Accessible
High costs have long limited access to pertuzumab in India, restricting treatment options for many HER2-positive breast cancer patients. With the launch of Pertuza, Alkem is expanding availability through its manufacturing capabilities. The company is also leveraging its robust oncology distribution network to make this life-saving therapy more affordable and accessible.
Commitment to Combating Breast Cancer
“Breast cancer is the most common cancer among Indian women, and addressing its growing burden requires treatments that are effective, accessible, and affordable,” said Dr. Vikas Gupta, CEO, Alkem Laboratories. “Oncology is a priority area for Alkem. The launch of Pertuza reflects our commitment to combining scientific excellence with wider patient access, and it will help thousands of women every year who would otherwise be excluded from this critical therapy,” Dr. Gupta added.
Strengthening Alkem’s Oncology Portfolio
Pertuza adds to Alkem’s expanding oncology portfolio, which already includes biosimilars for cetuximab, denosumab, bevacizumab, and romiplostim, among others. As reported by thehindubusinessline.com, the company continues to focus on developing innovative and affordable treatment options for patients across India.
